EnteroMedics, which is developing an implantable therapeutic device to treat obesity, decreased its IPO range to $8 to $9 from the originally proposed $14 to $16 range. The company plans to offer 5 million shares and use the proceeds to fund clinical trials and build a sales force. J.P. Morgan and Morgan Stanley are the joint book runners on the deal.
